CU6 Stock Overview
A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Clarity Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.10 |
| 52 Week High | AU$8.98 |
| 52 Week Low | AU$1.80 |
| Beta | 1.69 |
| 1 Month Change | -27.82% |
| 3 Month Change | -52.49% |
| 1 Year Change | 128.41% |
| 3 Year Change | 439.47% |
| 5 Year Change | n/a |
| Change since IPO | 177.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| CU6 | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -11.1% | -6.9% | -0.5% |
| 1Y | 128.4% | -10.6% | 8.2% |
Return vs Industry: CU6 exceeded the Australian Pharmaceuticals industry which returned -10.6% over the past year.
Return vs Market: CU6 exceeded the Australian Market which returned 8.2% over the past year.
Price Volatility
| CU6 volatility | |
|---|---|
| CU6 Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: CU6 has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CU6's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 50 | Michelle Parker | www.claritypharmaceuticals.com |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
Clarity Pharmaceuticals Ltd Fundamentals Summary
| CU6 fundamental statistics | |
|---|---|
| Market cap | AU$1.28b |
| Earnings (TTM) | -AU$42.32m |
| Revenue (TTM) | AU$11.51m |
111.3x
P/S Ratio-30.3x
P/E RatioIs CU6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CU6 income statement (TTM) | |
|---|---|
| Revenue | AU$11.51m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$11.51m |
| Other Expenses | AU$53.83m |
| Earnings | -AU$42.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -367.83% |
| Debt/Equity Ratio | 0% |
How did CU6 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 18:37 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clarity Pharmaceuticals Ltd is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Madeleine Williams | Canaccord Genuity |
| David Stanton | Jefferies LLC |